Vanda Pharmaceuticals (NASDAQ:VNDA) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report released on Thursday morning, MarketBeat.com reports. The firm issued an overweight rating and a $11.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on Vanda Pharmaceuticals in a report on Thursday, July 4th. They set a […]
More Stories
Federal Reserve Minutes Reflect Ongoing Divergence Over Interest Rates
By Andrew Moran The Federal Reserve’s December meeting proved far more fractured than the final vote suggested, underscoring the persistent...
US, Allied Forces Have Killed or Captured More Than 2 Dozen ISIS Operatives in Syria
By Jacob Burg The United States and its partner forces have captured or killed nearly 25 operatives of the ISIS...
Beijing Invokes ‘Make America Great Again’ in Rare Bid to Ease US Tensions
By Michael Zhuang From Dec. 26 to 29, Chinese state media published a rare series of editorials striking a conciliatory...
Judge Blocks White House’s Attempt to Defund Consumer Watchdog Agency
By Jack Phillips A federal judge ruled Tuesday that the White House cannot lapse its funding of the Consumer Financial...
Top 11 Hottest News Anchors in the World of All Time
News anchors have become a part of global personality. They are no longer just people who read headlines. Now, viewers...
OpenAI Looking to Hire ‘Head of Preparedness’ to Tackle AI Dangers
By Naveen Athrappully OpenAI is seeking to hire a candidate for the post of “Head of Preparedness” to tackle dangers...